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An occlusive thrombus was produced by thrombin-in-
duced coagulation in the left anterior descending coro-
nary artery of 18 open chest baboons. In six control
animals, occlusive thrombosis persisting for 4 hours re-
sulted in a large transmural infarct (66 :t 4% of the
perfusion area, mean :t SEM). In six animals, single
chain urokinase-type plasminogen activator, obtained by
recombinant deoxyribonucleic acid (DNA) technology,
was infused intravenously at a rate of 20 Ilg/kg per min
for 60 minutes after approximately 45 minutes of coro-
nary thrombosis. Persistent reperfusion occurred within
21 :t 4 minutes (mean :t SD). The mean duration of
occlusion before reperfusion was 72 :t 6 minutes. Re-
canalization resulted in a reduction of infarct size (42 :t
4%, P < 0.01 versus control animals). Myocardial blood
ftowin the perfusion area of the left anterior descending
coronary artery was 107% of normal 2.5 hours after
recanalization. The infusion of recombinant single chain
urokinase-type plasminogen activator was not associated
with systemic activation of the fibrinolytic system, fi-
brinogen breakdown or evident bleeding.
In six baboons recombinant low molecular weight
urokinase (molecular weight 33,000) was infused intra-
Coronary thrombolysis is currently under investigation as a
means to reduce myocardial infarct size, and several efforts
have been undertaken to develop fibrin-specific thrombolytic
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venously at a rate of 20 Ilg/kg per min for 60 minutes
after approximately 45 minutes of coronary thrombosis.
Persistent reperfusion occurred within 14 :t 5 minutes
(p < 0.05 versus recombinant single chain urokinase-
type plasminogen activator). The mean duration of oc-
clusion was 69 :t 14 minutes. Recanalization resulted
in a reduction of infarct size (45 :t 8%, p < 0.05 versus
control animals), and myocardial blood ftow in the per-
fusion area of the left anterior descending coronary ar-
tery was 97% of normal 2.5 hours after recanalization.
Infusion of recombinant lowmolecular weight urokinase
was associated with complete fibrinogen breakdown, a
decrease of alphaj-antiplasmin to less than 20% and
profuse bleeding from the surgical wounds.
It is concluded that intravenous infusion of recom-
binant single chain urokinase-type plasminogen activa-
tor may recanalize thrombosed coronary vesselswithout
inducingsystemiclysis. Recombinantlowmolecularweight
urokinase appears to have a comparable or somewhat
higher thrombolytic effect but is associated with exten-
sive systemic fibrinolytic activation.
(J Am Coil Cardiol1986;8:1I8-24)
agents (l,2). Human tissue-type plasminogen activator has
been investigated in four multicenter trials which have es-
tablished that it is an efficient thrombolytic agent with rel-
atively high but not absolute fibrin specificity (3).
Different types of single chain urokinase-type plasmin-
ogen activators, alternatively designated prourokinase or
single chain urokinase, have also been demonstrated to in-
duce clot-specific thrombolysis in animal models of throm-
bosis (4-9). In dogs with coronary thrombosis induced by
a copper coil, single chain urokinase-type plasminogen ac-
tivator isolated from conditioned cell culture media was
shown to induce reperfusion without systemic fibrinogen
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breakdown when infused intravenously at a sufficiently high
rate (7).
In the present study, we used a primate species (baboon)
to establish whether high dose systemic infusion of single
chain urokinase-type plasminogen activator, obtained by
recombinant DNA technology (10), can induce coronary
thrombolysis without the association of systemic fibrinolytic
activation, and to evaluate the beneficial effect of reperfu-
sion on the ischemic ventricle. Therefore, coronary angi-
ography was supplemented with measurements of regional
myocardial blood flow and determination of infarct size 4
hours after the coronary occlusion.
Methods
Experimental preparation. Eighteen baboons (Papio
anubis) of either sex, weighing 7 to 12 kg, were anesthetized
with ketamine hydrochloride (Ketalar, Duphar, Amsterdam,
The Netherlands), 10 mg/kg body weight and atropine, 0.06
mg/kg intramuscularly, after premedication with diazepam
(Valium, Hoffmann-LaRoche, Basel, Switzerland), 5 mg
intramuscularly. After endotracheal intubation, the lungs
were ventilated with a Bird Mark 7 respirator (Bird Cor-
poration). Anesthesia was maintained with pentobarbital
(Nembutal, Abbott Laboratories), 30 mg/kg intravenously.
Blood gas analysis was performed repeatedly throughout
the experiment using a pH blood gas microanalyzer (166;
Coming Glass Works). Catheters were inserted into the
descending aorta and the right atrium through the right fem-
oral artery and vein for the measurement of aortic and central
venous pressures. A catheter (5F Lehman, USCI) was in-
serted through the left carotid artery and angiography of the
right and left coronary arteries was made. Next, a sternot-
omy was performed and the heart was suspended in a peri-
cardial cradle. A small tube was inserted into the left atrium
to measure left atrial pressure and to inject tracer micro-
spheres (NEN Chemicals GmbH, Dreieich, West Germany).
For calibrating the tracer microsphere values, arterial blood
was withdrawn at a constant speed from the descending
aorta using a multispeed transmission pump (Harvard Ap-
paratus Co., Inc.). The left anterior descending coronary
artery was dissected free over a small segment to produce
a coronary thrombus as described later.
To monitor hemodynamic variables, systolic and dia-
stolic aortic pressure, left atrial pressure, lead II electro-
cardiogram and heart rate were registered on a multichannel
recorder (Siemens Corp., Solna, Sweden) throughout the
experiment.
Experimental protocol. Ten minutes after sternotomy
and preparation of the left anterior descending coronary
artery, recording of preischemic hemodynamic data was
started. Thereafter, a 1 em long left anterior descending
coronary artery segment was ligated at its proximal and
distal end using 7-0 Prolene snares, and thrombin (10 JLI of
100 National Institutes of Health units/ml) was injected in
the isolated vessel segment. The segment was repeatedly
crushed with a small forceps. After 15 minutes the Prolene
snares were released. This resulted in a clearly visible lo-
calized thrombus occluding the left anterior descending
coronary artery, which was confirmed by coronary angi-
ography. Twenty minutes after left anterior descending
coronary artery occlusion, an injection of tracer micro-
spheres was made for the quantitation of regional myocardial
blood flow.
After approximately 45 minutes of coronary thrombosis,
recombinant single chain urokinase-type plasminogen ac-
tivator or recombinant low molecular weight urokinase (20
JLg/kg per min) was infused for 60 minutes through the right
brachial vein (six baboons in each group). Coronary reper-
fusion was monitored by visual inspection of the occluded
artery and confirmed by control coronary angiography. Im-
mediately after thrombolysis, the animals were heparinized
to prevent rethrombosis. During the infusion, blood samples
were collected from the left brachial vein into 0.01 M citrate
solutionto determinefibrinogen, alpha-antiplasmin and single
chain urokinase-type plasminogen activator antigen levels
as previously described (7). Six other baboons served as a
control group. They underwent the same experimental pro-
cedure except for the infusion. They were heparinized 60
minutes after left anterior descending coronary artery oc-
clusion.
Infarct size measurement. During left anterior descend-
ing coronary artery occlusion or reperfusion, or both, all
animals received lidocaine (Xylocaine, Goteborg, Sweden),
20 JLg/kg intravenously. Two and a half hours after reca-
nalization or 4 hours after acute occlusion of the left anterior
descending coronary artery, a second tracer microsphere
injection was made in all animals. The animals were then
killed with an overdose of pentobarbital and the heart was
removed. Infarct size was measured by triphenyltetrazolium
staining and expressed as a percent of the perfusion area of
the left anterior descending coronary artery, as previously
described (11). The area at risk was expressed as a percent
of the left ventricular mass.
Regional myocardial blood flow. This was measured with
radioactive tracer microspheres, as previously described
(12,13). The left ventricular slices were unrolled and divided
into subepicardial and subendocardial samples (± 1 g tissue
blocks). Gamma spectrometry was carried out on all tissue
and blood samples (14) with a multichannel analyzer (ND66,
Nuclear Data, Inc.) and computer terminal (Nuclear Data,
Inc.). Four differently labeled microspheres were used: ce-
rium-141, tin-1l3, ruthenium-l03 and niobium-95.
Thrombolytic agents. The recombinant single chain
urokinase-type plasminogen activator was obtained by
expression of the human cDNA coding for full length pro-
urokinase, a peptide chain of 411 amino acids (molar mass
120 FLAMENG ET AL.
CORONARY THROMBOLYSIS WITH RECOMBINANT scu-PA
JACC Vol. 8. No. I
July 1986:118-24
A
8
after thrombolysis, myocardial blood flow was homoge-
neously distributed in the left anterior descending and cir-
cumflex artery areas (Table 1, Fig. 2).
Effects of reperfusion on infarct size. Occlusion of the
left anterior descending coronary artery for 4 hours resulted
in large transmural infarcts in all six control baboons. The
mean percent of the perfusion area of the occluded artery
showing infarction was 66 ± 4% (mean ± SEM). In the
six baboons undergoing reperfusion with recombinant single
chain urokinase-type plasminogen activator, the percent of
Figure 1. Coronary arteriograms before and after intravenous
administration of recombinant single chain urokinase-type plas-
minogen activator in a baboon with thrombotic occlusion of the
left anterior descending coronary artery. A, After thrombotic oc-
clusion (asterisk). B, After reperfusion.
Results
Coronary thrombolysis. Coronary thrombolysis was
achieved in all 12 baboons receiving an infusion of either
recombinant single chain urokinase-type plasminogen ac-
tivator (n = 6) or recombinant low molecular weight uro-
kinase (n = 6). The time to reperfusion was 21 ± 4 minutes
(mean ± SD) for recombinant single chain urokinase-type
plasminogen activator and 14 ± 5 minutes for recombinant
low molecular weight urokinase (p < 0.05). The mean
duration of coronary occlusion before reperfusion was 72
± 6 minutes for recombinant single chain urokinase-type
plasminogen activator and 69 ± 14 minutes for recombinant
low molecular weight urokinase. Acute reocclusion of the
left anterior descending coronary artery was not observed.
Figure 1 shows angiographic evidence of thrombolysis in a
typical experiment. In the control group, complete occlusion
of the left anterior descending coronary artery persisted
throughout the experiment in all six animals.
Regional myocardial blood flow. Acute thrombosis of
the left anterior descending coronary artery resulted in a
severe reduction of myocardial blood flow in its perfusion
area (Fig. 2). This relatively low collateral flow (14, 20 and
16% of flow to the nonoccluded area in the three groups,
respectively) persisted in the control group with permanent
coronary artery occlusion (Fig. 2). In both the recombinant
single chain urokinase-type plasminogen activator and re-
combinant low molecular weight urokinase groups, lysis of
the coronary thrombus resulted in a reactive hyperemia in
the left anterior descending coronary artery area as evi-
denced by a persisting visible blush. Two and a half hours
46,420 daltons), in Escherichia coli (10). Recombinant sin-
gle chain urokinase-type plasminogen activator was purified
carefully avoiding conversion to two chain urokinase forms.
The isolated protein was unglycosylated and migrated as a
main band with molecular weight 47,000 on sodium do-
decylsulfatepolyacrylamide gel electrophoresis under native
and reducing conditions. It had a specific activity of 175,000
Il.l/rng as measured on chromogenic substrate (S-2444, Kabi
Diagnostica, Stockholm, Sweden) after activation with plas-
min and was devoid of urokinase activity and pyrogens.
The recombinant low molecular weight urokinase was
obtained from the same recombinant Escherichia coli strain
as recombinant single chain urokinase-type plasminogen ac-
tivator (10) after conversion of the primary expression prod-
uct during purification. The isolated protein proved to be
unglycosylated but otherwise structurally identical and func-
tionally equivalent to low molecular weight urokinase from
human urine (15). Recombinant low molecular weight uro-
kinase (molar mass 30,852 daltons) had a specific activity
of 360,000 IV/mg as measured on chromogenic substrate
and was devoid of pyrogens.
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Figure 2. Regional myocardial blood flow (MBF) distribution
after left anterior descending (LAD) coronary artery occlusion
(OCCL) and at the end of the experiment. The results represent
the mean ± SEM of the left anterior descending coronary artery-
myocardial blood flow values, expressed as percent of thecircum-
flex coronary artery (CX)-myocardial blood flow values. A =
control group; B = recombinant low molecular weight urokinase;
C = recombinant single chain urokinase-type plasminogen acti-
vator.
infarcted tissue was significantly lower than that in the con-
trol animals: 42 ± 4% (p < 0.(01) (Fig. 3). In the six
baboons undergoing reperfusion with recombinant low mo-
lecular weight urokinase the percent of infarcted tissue was
also significantly lower than that in the control animals: 45
± 8% (p < 0.05).
In the control group, none of the infarcts were hemor-
rhagic. After about 70 minutes of coronary thrombosis,
reperfusion induced macroscopically visible hemorrhage in
10 of the 12 animals. Characteristically, the hemorrhage
was located in the midwall and never extended outside the
infarct into viable myocardium.
The volume of the perfusion area of the occluded artery
was not different between the recombinant single chain uro-
kinase-type plasminogen activator group (17 ± 3%) or the
recombinant low molecular weight urokinase group (22 ±
4%) and the control group (23 ± 3%) (p > 0.05).
Hemodynamic changes. Both in the animals with per-
manent left anterior descending coronary artery occlusion
and in animals with reperfusion, the main hemodynamic
variables (heart rate, aortic pressure and left atrial pressure)
remained essentially unchanged throughout the experiment
(Table 2). In the animals with reperfusion, the incidence of
arrhythmias (ventricular ectopic beats or runs of ventricular
tachycardia) was, however, higher than in the group with
permanent coromary artery occlusion. Throughout the ex-
periments, blood pH, partial oxygen tension, partial carbon
dioxide tension, bicarbonate and total carbon dioxide levels
were kept within normal limits.
Changes in hemostatic variables and bleeding. During
infusion of recombinant single chain urokinase-type plas-
minogen activator, a steady state plasma level of 6 ± 2
jLg/ml was maintained. After cessation of the infusion, the
plasminogen activator antigen disappeared from plasma with
an initial half-life of 5 minutes but the disappearance curve
was not monotone (Fig. 4). Infusion of recombinant single
chain urokinase-type plasminogen activator was not asso-
ciated with systemic fibrinolytic activation because after the
infusion, the fibrinogen and the alpha--antiplasmin levels
had not significantly changed as compared with those in the
control group (Fig. 5). Bleeding from the puncture site in
the coronary artery was observed in two animals, but profuse
bleeding from surgical wounds was not observed.
Infusion of recombinant low molecular weight urokinase
caused extensive systemic fibrinolytic activation with total
depletion of both fibrinogen and alphayantiplasmin. This
was reflected by profuse bleeding from surgical wounds in
five of the six baboons infused with this agent.
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Table 1. Regional Myocardial Blood Flow (mllmin per 100 g)
Circumflex Coronary Artery Area Left Anterior Descending Coronary Artery Area
Epi Endo Total Epi Endo Total
30 minute LAD thrombosis
Control group (n = 6) 175 ± 118 194 ± 105 185 ± III 19 ± 21* 37 ± 33* 28 ± 27*
rscu-PA group (n = 6) 172 ± 70 193 ± 100 183 ± 86 20 ± 12* 43 ± 29* 31 ± 20*
rL-UK group (n = 6) 134 ± 46 143 ± 38 138 ± 41 16 ± 12* 19 ± 11* 17 ± 11*
240 minute LAD thrombosis
Control group 188 ± 118 226 ± 197 207 ± 163 19 ± 19* 35 ± 35* 27 ± 27*
150 minute reperfusion
rscu-PA group 109 ± 43 125 ± 60 117 ± 51 105 ± 44 148 ± 84 125 ± 59
rL-UK group 94 ± 27 108 ± 28 101 ± 27 89 ± 29 106 ± 36 96 ± 30
*p < 0.001 versus circumflex value. Endo = subendocardial layer; Epi = subepicardial layer; rL-UK = recombinant low molecular weight urokinase;
rscu-PA = recombinant single chain urokinase-type plasminogen activator. The data represent mean values ± SO.
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Figure 3. Effect of reperfusion on infarct size. The values rep-
resent mean ± SEM of the mass of infarcted tissue, expressed as
percent of the mass of the perfusion bed of the occluded artery.
A = control group; B = recombinant single chain urokinase-type
plasminogen activator (rscu-PA); C = recombinant low molecular
weight urokinase-type plasminogen activator (rL-UK).
Discussion
Coronary thrombolysis. This study demonstrates that
intravenous administration of recombinant single chain uro-
kinase-type plasminogen activator can effectively produce
coronary thrombolysis in primates, which confirms and ex-
tends our findings with human single chain urokinase-type
plasminogen activator and coronary thrombolysis in dogs
Table 2. Hemodynamic Data
TIME (minutes)
Figure 4. Single chain urokinase-typeplasminogenactivator (scu-
PA)-associated antigen levels in plasma during and after intrave-
nous infusion of this plasminogen activator at a rate of 20 Mg/kg
per min for 60 minutes. The results represent the mean ± SD.
The disappearance rate after cessation of the infusion occurs with
an initial half-life of 5 minutes.
(7). The time to achieve thrombolysis (21 ± 4 minutes) in
this study is comparable with that achieved in dogs with
natural single chain urokinase-type plasminogen activator
(23 ± 2 minutes). Interestingly, a significantly shorter mean
time to reperfusion (14 ± 5 minutes) was observed with
Heart Rate LAP AoP-s AoP-d
(beats/min) (mmHg) (mm Hg) (mm Hg)
Preischemia
Control group (n = 6) 154 ::t 19 5 ::t 2 109::t 18 80 ::t 10
rscu-PA group (n = 6) 157 ::t 20 3 ::t 2 112 ± 19 85 ± 18
rL-UK group (n = 6) 152 ::t 21 5 ::t 1 120 ± 14 92 ::t 11
30 minute LAD thrombosis
Control group 164 ::t 19 8 ::t 5 112::t 11 83 ::t 14
rscu-PA group 159 ::t 17 4 ::t 2 109:!: 13 84 ± 15
rL-UK group 153 ± 22 5 ± 2 117 ± 9 91 ± 8
240 minute LAD thrombosis
Control group 153 ± 24 7 ± 3 103 ::t 21 69 ± 25
150 minute reperfusion
rscu-PA group 157 ± 29 2 ± I 106 ± 17 83 ± 19
rL-UK group 156 ± 25 2 ± 1 103 ::t 10 73 ± 12
AoP-d = diastolic aortic pressure; AoP-s = systolic aortic pressure; LAP = left atrial pressure; other
abbreviations as in Table I. The data represent mean values ± SO.
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recombinant low molecular weight urokinase (p < 0.05),
This is probably explained by the twofold higher specific
activity (360,000 versus 175,000 IV/mg) of the low mo-
lecular weight urokinase relative to that of the single chain
urokinase-type plasminogen activator. Thus, with equal in-
fusion rates on a weight basis, twice the total activity was
administered to the animals receiving low molecular weight
urokinase, resulting in shorter reperfusion times.
Effects of reperfusion on infarct size. The impact of
coronary reperfusion on the reduction of infarct size was
only moderate, not an unexpected observation. This is con-
sistent with a previous report (11) demonstrating the severe
time constraints on coronary occlusion in baboons.
Regional myocardial blood Dow. Despite the lack of a
more significant impact on myocardial infarct size, a sur-
prising absence of the no-reflow phenomenon (that is, the
severe impairment of tissue perfusion in the recanalized zone
[16,17]) was found. Recanalization was associated with per-
fect distribution of myocardial blood flow in the recanalized
zone. This is distinct from results previously obtained in
the same model with recombinant tissue-type plasminogen
activator (11), where post-thrombotic flow was impaired.
One possible explanation for this discrepancy is the longer
postreperfusion infusion time of the thrombolytic agents
utilized in the present study. This may have resulted in more
complete lysis of microvascular thrombi.
Pharmacokinetics of recombinant single chain uro-
kinase-type plasminogen activator. The pharmacokinetic
behavior of this plasminogen activator was comparable with
that observed with other preparations of single chain uro-
kinase-type plasminogen activator in other species. A some-
what higher steady state level (6 JLg/ml) was achieved than
with a similarly effective administration of natural single
chain urokinase-type plasminogen activator in dogs (3 JLglml)
(7). However, the plasma half-lives were similarly short, 5
and 7 minutes, respectively. The only other measurement
of the clearance rate for recombinant single chain urokinase-
type plasminogen activator was obtained after a single in-
travenous injection in rabbits where a half-life of3.5 minutes
resulted (18). In tile present study as well as in other studies
with thrombolytic infusions of single chain urokinase-type
plasminogen activator, disappearance rate curves from plasma
were not monotone. These short half-lives will probably
make the use of continuous drug infusions necessary for
effective thrombolytic therapy.
Therapeutic implications. An important aspect of this
study is the demonstration of the fibrin-specific thrombolytic
potential of recombinant single chain urokinase-type plas-
minogen activator. With peak plasma levels of 6 JLg/ml
maintained for 45 minutes, no decrease in either alphaz-
antiplasmin or fibrinogen levels occurred, which is indic-
ative of a high degree of fibrin specificity. The resulting
maintenance of normal systemic fibrinolytic function par-
allel with a site-specific thrombolytic effect is an attractive
therapeutic quality with which risks of hemorrhage may be
reduced. In this study the apparent lack of bleeding seen
with the animals receiving recombinant single chain uro-
kinase-type plasminogen activator contrasted sharply with
the hemorrhaging at incisional and vessel puncture sites of
the recombinant low molecular weight urokinase-treated ba-
boons. Still, one must use caution in the extrapolation of
relative fibrin specificity of thrombolytic agents from animal
models to humans, because interspecies variability in sen-
sitivity of the fibrinolytic system to activation is marked.
Nonetheless, recombinant single chain urokinase-type plas-
minogen activator offers promise as an intravenous agent
for effective and specific thrombolytic therapy of acute myo-
cardial infarction in humans.
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